4.81

3.41% -0.17

Cogent Biosciences Inc (COGT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Cogent Biosciences Inc stock is traded at $4.81, with a volume of 708.35K. It is down -3.41% in the last 24 hours and up +7.85% over the past month. Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Previous Close:

$4.98

Open:

$4.98

24h Volume:

708.35K

Relative Volume:

0.53

Market Cap:

$668.34M

Revenue:

Net Income/Loss:

$-242.30M

P/E Ratio:

-1.9395

EPS:

-2.48

Net Cash Flow:

$-192.10M

1W Performance:

-18.06%

1M Performance:

+7.85%

6M Performance:

-52.89%

1Y Performance:

-39.27%

1-Day Range:

$4.81

$5.14

1-Week Range:

$4.5505

$5.875

52-Week Range:

$3.72

$12.61

Cogent Biosciences Inc Stock (COGT) Company Profile

Name

Cogent Biosciences Inc

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

617-945-5576

Address

275 WYMAN STREET, WALTHAM

Employee

205

Twitter

Next Earnings Date

2024-10-31

Latest SEC Filings

COGT's Discussions on Twitter

Compare COGT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
COGT Cogent Biosciences Inc	4.81	668.34M	0	-242.30M	-192.10M	-2.48
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Dec-11-24	Downgrade	Needham	Buy → Hold
Feb-26-24	Downgrade	Robert W. Baird	Outperform → Neutral
Feb-08-24	Initiated	Citigroup	Buy
Dec-11-23	Downgrade	Wedbush	Outperform → Neutral
Dec-08-23	Initiated	JP Morgan	Overweight
Apr-28-23	Initiated	Robert W. Baird	Outperform
Mar-27-23	Resumed	H.C. Wainwright	Buy
Dec-14-22	Initiated	Needham	Buy
Jun-28-22	Initiated	Guggenheim	Buy
Oct-11-21	Initiated	H.C. Wainwright	Buy
Jun-09-21	Resumed	Jefferies	Buy
Dec-23-20	Initiated	Piper Sandler	Overweight
Oct-14-20	Initiated	Ladenburg Thalmann	Buy

View All

Cogent Biosciences Inc Stock (COGT) Latest News

04:09 AM

Robert W. Baird Cuts Cogent Biosciences (NASDAQ:COGT) Price Target to $7.00 - Defense World

04:09 AM

May 08, 2025

Cogent Biosciences (NASDAQ:COGT) Releases Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat

May 08, 2025

May 07, 2025

Stock Surge: Cogent Biosciences Inc (COGT) Closes at 4.70, Marking a -15.62 Increase/Decrease - DWinneX

May 07, 2025

Cogent Biosciences (COGT) Maintains Neutral Rating Amid PT Adjustment | COGT Stock News - GuruFocus

May 07, 2025

Cogent Biosciences (COGT) Price Target Reduced by Baird | COGT Stock News - GuruFocus

May 07, 2025

MetLife Investment Management LLC Has $443,000 Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

May 07, 2025

Invesco Ltd. Sells 455,437 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat

May 07, 2025

May 06, 2025

Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - Barchart.com

May 06, 2025

Wedbush Trims Price Target on Cogent Biosciences to $10 From $11, Maintains Neutral Rating - marketscreener.com

May 06, 2025

Cogent Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 06, 2025